当前位置：
X-MOL 学术
›
Cancer Manage. Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
Cancer Management and Research ( IF 2.5 ) Pub Date : 2021-09-14 , DOI: 10.2147/cmar.s326255 He-Jiun Jiang , Yen-Hsiang Chang , Yen-Hao Chen , Che-Wei Wu , Pei-Wen Wang , Pi-Jung Hsiao
Cancer Management and Research ( IF 2.5 ) Pub Date : 2021-09-14 , DOI: 10.2147/cmar.s326255 He-Jiun Jiang , Yen-Hsiang Chang , Yen-Hao Chen , Che-Wei Wu , Pei-Wen Wang , Pi-Jung Hsiao
Background: Lenvatinib treatment of 24 mg/day for radioiodine-refractory differentiated thyroid carcinoma (RRDTC) patients was almost intolerable, with high rates of dose reduction, interruption and discontinuation. Balancing treatment safety with disease risks remains challenging, and the appropriate dosage remains unclear in Asia.
Patients and Methods: A total of 65 RRDTC patients treated with lenvatinib were retrospectively collected from Oct. 2015 to Jun. 2020 from two medical centers of South Taiwan. The drug tolerability, treatment efficacy and clinical outcomes were analyzed.
Results: Different doses of lenvatinib were initiated but ultimately maintained with a median dose of 10 mg/day within the first 3 months. The disease control rate reached 89.2%, including 24.6% partial response and 64.6% stable disease. Disease progression occurred in 10.8% of patients and increased to 40.0% at the end. Eventually, the treatment dose achieved a median progression-free survival (PFS) of 26.1 months (95% CI: 17.1-NA) with overall survival (OS) not reached yet (24.1∼NA). Overall, the 48-month PFS rate was 35.6% (95% CI: 18.5– 68.4) and 48-month OS was 54.3% (95% CI: 41.2– 71.7). The dose was tolerable with a dose reduction rate of 44.6%, dose interruption rate of 40.0% and fewer high-graded adverse events. The drug discontinuation rate was only 3.1%. However, RRDTC patients with bone metastasis or maximal dose exposure to RAI (≥ 600 mCi) may have less efficacy to the low maintenance dose treatment.
Conclusion: Assessing treatment intensity, safety and efficacy, low-dose lenvatinib treatment was well tolerated by RRDTC patients and displayed acceptable drug efficacy and outcomes.
更新日期：2021-09-13
Patients and Methods: A total of 65 RRDTC patients treated with lenvatinib were retrospectively collected from Oct. 2015 to Jun. 2020 from two medical centers of South Taiwan. The drug tolerability, treatment efficacy and clinical outcomes were analyzed.
Results: Different doses of lenvatinib were initiated but ultimately maintained with a median dose of 10 mg/day within the first 3 months. The disease control rate reached 89.2%, including 24.6% partial response and 64.6% stable disease. Disease progression occurred in 10.8% of patients and increased to 40.0% at the end. Eventually, the treatment dose achieved a median progression-free survival (PFS) of 26.1 months (95% CI: 17.1-NA) with overall survival (OS) not reached yet (24.1∼NA). Overall, the 48-month PFS rate was 35.6% (95% CI: 18.5– 68.4) and 48-month OS was 54.3% (95% CI: 41.2– 71.7). The dose was tolerable with a dose reduction rate of 44.6%, dose interruption rate of 40.0% and fewer high-graded adverse events. The drug discontinuation rate was only 3.1%. However, RRDTC patients with bone metastasis or maximal dose exposure to RAI (≥ 600 mCi) may have less efficacy to the low maintenance dose treatment.
Conclusion: Assessing treatment intensity, safety and efficacy, low-dose lenvatinib treatment was well tolerated by RRDTC patients and displayed acceptable drug efficacy and outcomes.
京公网安备 11010802027423号